Supplementary Figure S4 from The Impact of Concordance between Liquid and Tissue Biopsy for Actionable Mutations: Insights from the ROME Trial

2026 Open access

Read full text
Authors: Andrea Botticelli, Chiara Cremolini, Simone Scagnoli, Mauro Biffoni, Sara Lonardi, Lorenzo Fornaro, Valentina Guarneri, Ugo De Giorgi, Paolo A. Ascierto, Giovanni Blandino, Giulia d’Amati, Massimo Aglietta
+34 more PierFranco Conte, Edoardo Crimini, Maurizio Ceracchi, Simona Pisegna, Sofia Verkhovskaia, Roberto Bordonaro, Sergio Bracarda, Giovanni Butturini, Lucia Del Mastro, Andrea DeCensi, Agnese Fabbri, Elisabetta Fenocchio, Stefania Gori, Giulio Metro, Annamaria Pessino, Daniele Pozzessere, Fabio Puglisi, Stefano Tamberi, Alberto Zambelli, Donatella Marino, Ettore Domenico Capoluongo, Federico Cappuzzo, Bruna Cerbelli, Giuseppe Giannini, Umberto Malapelle, Federica Mazzuca, Marianna Nuti, Giancarlo Pruneri, Maurizio Simmaco, Lidia Strigari, Giuseppe Tonini, Nello Martini, Giuseppe Curigliano, Paolo Marchetti
DOI: 10.1158/1078-0432.31006905
Cited by: 0

Abstract

Supplementary Figure S4. Figure showing progression-free survival in liquid only group.

Fields of Study & Subjects

Cancer Genomics and Diagnostics Lung Cancer Treatments and Mutations PARP inhibition in cancer therapy

Publication details

Publication date
6 January 2026